domized, double-blind placebo controlled cohort studies (Stockholm, Sweden; Goteberg, Sweden; Italy). The lowest efficacy of a DTaP reported was 59% (95% Cl 51 to 86; SmithKline Beecham, Rixensart, Belgium) using a PT-and FHA-containing DtaP; the addition of 69K to this vaccine increased the protective efficacy to 84% (95% Cl 76 to 89, SmithKline Beecham; 95% Cl 76 to 90; Chiron/Biocine, Siena, Italy), suggesting an incremental benefit of 69K. A PT monocomponent vaccine also resulted in a lower efficacy of 71% (95% CI 63 to 78; Amvax, Maryland) suggesting that there may be incremental benefit with the inclusion of FHA. Further addition of FIM to PT, FHA, and 69K did not increase the protective efficacy (85%, 95% CI 81 to 89; Connaught Laboratories Ltd); however, preliminary data may suggest better protection against milder disease with this multicomponent product.
Although these 'soft' inferences may be made from these clinical trials, the data from some of the other efficacy studies using other study designs complicate the situation. In Munich, Germany a PT/FHA vaccine had an efficacy of 89% (95% CI 77 to 95; Connaught Laboratories Inc, Pennsylvania) in a prospective case-control study design. Another PT/PHA vaccine had an efficacy of 83% (95% CI 61 to 93; Pasteur-Merieux, Lyon, France) in Senegal, West Africa using a prospective, randomized double-blind cohort design with a parallel diphtheria and tetanus vaccine (DT) nonstudy control group. In Erlangen, Germany, a vaccine with PT, FHA, 69K and FIM (Wyeth-Lederle) had an efficacy of 74% after three doses and 82% after four doses in a randomized, double-blind cohort study design with an open, randomized DT cohort control. Finally, in Mainz, Germany, the same PT/FHA/69K-containing vacc ine that had been used in Italy had an efficacy of 89% (95% CI 77 to 95, SmithKline Beecham) in a prospective blinded household contact study. In addition to differences in study design, different immunization schedules (two, four, six months; three, four, five months; or three, five, 12 months) and the number of doses administered (three or four) may also have contributed to the difference in efficacy observed.
The striking similarities in the efficacy of the DTaP vaccines is in marked contrast to the wide range of efficacy demonstrated with the whole-cell pertussis vaccines. The effect of study design and dosing frequency may have even more influ- ence on the results observed with th e whole-cell pertussis vaccines than with the acellular pertussis vaccines. In Italy, the effi cacy of three doses of the American Conn aught vaccine was 36% (95% CI 14 to 52) whereas the same vaccine had an efficacy of 48% (95% CI 37 to 58) in the Stockholm trial. The Wyeth -Lederl e whole-cell vaccine had an efficacy of 85% after three doses and 93% after four doses , while a French and German whole-cell vaccine had efficacies in excess of 95% in Senegal , Mainz and Munich. Parenthetically, there are no data available from these studies about the efficacy of the wholecell pertussis vaccine in use in Canada; however, recent epidemiological data suggest an efficacy well below that demonstrated with the acellular pertussis vaccines.
From these recent studies, it can be concluded that the acellular pertussis vaccines are safe and efficacious and , if the manufacturers choose to license the products in Canada, there will be a number of excell ent products available for use. The selection of a particular product may well involve factors other than safety and efficacy, such as cost, availability and ability to combine it with other vaccines given concurrently. Vaccine providers will need to awa it further analysis of this wea lth of 360 data as well as recommendations from the Nationa l Advisory Committee on Immunization . 
